Wire · opportunities
Prime Medicine receives FDA clearance for PM647 in alpha-1 antitrypsin deficiency
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 September 2026 · Fusion42 review
Prime Medicine received FDA clearance for PM647, an in vivo prime editing therapy targeting alpha-1 antitrypsin deficiency, to begin first-in-human trials starting in 2027. The therapy aims to permanently correct the genetic defect causing the disease with a single treatment, differentiating it from existing augmentation and RNA-editing therapies.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 26 Sep 2026 and 28 Sep 2026.
◆ ◆ The Wire takeaway
You should watch PM647’s trial closely as it could open the market to permanent one-time gene correction for alpha-1 antitrypsin deficiency, challenging ongoing therapies reliant on repeated treatments. This clearance signals a shift towards DNA-level cures over RNA approaches that could reshape competition in genetic medicine for liver and lung diseases.
◆ Coverage
2 sources · first reported 26 Sep 2026 · latest 28 Sep 2026
◆ Related on Wire
◆ Topics